Brief: Xbiotech Says FDA Has Granted Permission To Commence Clinical Trials With Its Novel Drug Candidate For Treating Patients With Pancreatic Cancer
19/04/2021 09:12
April 19 (Reuters) - XBiotech Inc XBIT.O :
* XBIOTECH INC - FDA HAS GRANTED PERMISSION TO COMMENCE
CLINICAL
TRIALS WITH ITS NOVEL DRUG CANDIDATE FOR TREATING PATIENTS WITH
PANCREATIC CANCER
* XBIOTECH INC - FDA GIVES GO-AHEAD FOR XBIOTECH'S CANDIDATE
THERAPY FOR PHASE I/II DOUBLE-BLIND PLACEBO CONTROLLED STUDY IN
PANCREATIC CANCER
Source text for Eikon: ID:nGNX50rtQ6
Further company coverage: XBIT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on XBiotech
See all newsBrief: XBiotech Announces Positive Final Efficacy Results From Phase II Taskin Trial
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: Xbiotech Launches Phase Ii Clinical Trial Evaluating Vilamakitug For The Treatment Of Active Axial Spondyloarthritis
Brief: XBiotech Inc - John Simard To Retire As CEO Of XBiotech - SEC Filing
Brief: Xbiotech Announces Enrollment Completion Of Phase I Clinical Trial For Hutrukin, A Novel Candidate Therapy For Stroke